MARKET

ANIK

ANIK

Anika
NASDAQ

Real-time Quotes | Nasdaq Last Sale

39.62
+0.21
+0.53%
After Hours: 39.62 0 0.00% 16:42 09/24 EDT
OPEN
39.22
PREV CLOSE
39.41
HIGH
39.94
LOW
38.95
VOLUME
34.13K
TURNOVER
--
52 WEEK HIGH
48.37
52 WEEK LOW
32.04
MARKET CAP
571.44M
P/E (TTM)
-43.8080
1D
5D
1M
3M
1Y
5Y
Tactoset® Injectable Bone Substitute Now FDA Cleared for Hardware Augmentation
510(k) clearance expands the capability of Tactoset for augmenting suture anchor fixationBEDFORD, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedi...
GlobeNewswire · 09/14 13:00
Anika Therapeutics Secures Additional FDA Clearance For Tactoset's Expanded Use
MT Newswires · 09/14 10:54
Anika to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Fin...
GlobeNewswire · 09/07 14:00
5 Buy-Rated Small-Cap Biotech Stocks to Add to Your Watchlist
StockNews.com · 09/03 13:44
Anika to Debut Joint Preservation Portfolio at the 2021 AAOS Annual Meeting
Anika, now combined with Arthrosurface and Parcus Medical, meets the evolving unmet needs of surgeons in the global joint preservation marketBEDFORD, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preserva...
GlobeNewswire · 09/01 14:05
Return on Capital Employed Insights for Anika Therapeutics
After pulling data from Benzinga Pro it seems like during Q2, Anika Therapeutics (NASDAQ:ANIK) earned $9.18 million, a 629.73% increase from the preceding quarter.
Benzinga · 08/23 15:39
Worldwide Adhesion Barriers Industry to 2026 - Featuring Anika Therapeutics, Atrium Medical and Baxter International Among Others - ResearchAndMarkets.com
The "Adhesion Barriers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
Business Wire · 08/18 11:50
Global Aesthetic Injectables Market Share Expected to Gain USD 22,500 Million by 2026: Facts & Factors
Facts and Factors have published a new research report titled "Aesthetic Injectables Market By Type (Dermal Fillers, and Wrinkle Relaxers), By Application (Face Lift, Lipoatrophy Treatment, Facial Line Correction, Acne Scar Treatment, Lip Augmentation, ...
GlobeNewswire · 08/16 12:19
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANIK. Analyze the recent business situations of Anika through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANIK stock price target is 49.67 with a high estimate of 59.00 and a low estimate of 44.00.
EPS
Institutional Holdings
Institutions: 251
Institutional Holdings: 14.69M
% Owned: 101.85%
Shares Outstanding: 14.42M
TypeInstitutionsShares
Increased
47
674.92K
New
16
612.02K
Decreased
49
562.67K
Sold Out
21
861.81K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
President/Chief Executive Officer/Director
Cheryl Blanchard
Chief Financial Officer/Executive Vice President/Treasurer
Michael Levitz
Executive Vice President/General Counsel/Secretary
David Colleran
Executive Vice President/Director of Human Resources
Thomas Finnerty
Executive Vice President
James Loerop
Independent Director
John Henneman
Independent Director
Raymond Land
Independent Director
Glenn Larsen
Independent Director
Stephen Richard
Independent Director
Jeffery Thompson
Independent Director
Susan Vogt
No Data
About ANIK
Anika Therapeutics, Inc. is a joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care. It partners with physicians and develops minimally invasive products. It focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. Its product categories include joint pain management therapies, orthopedic joint preservation and restoration care, and other. The joint pain management therapies offer injectable viscosupplement products that provide pain relief from osteoarthritis conditions and its products include MONOVISC, ORTHOVISC, CINGAL and HYVISC. The Company's orthopedic joint preservation and restoration care products include HYALOFAST and TACTOSET. It also offers a line of surgical implant and instrumentation solutions that are used by surgeons to repair and reconstruct damaged ligaments and tendons due to sports injuries, trauma and disease.

Webull offers kinds of Anika Therapeutics Inc stock information, including NASDAQ:ANIK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIK stock methods without spending real money on the virtual paper trading platform.